Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use SINGULAIR safely and effectively. See full prescribing information for SINGULAIR. SINGULAIR® (montelukast sodium) tablets, for oral use SINGULAIR® (montelukast sodium) chewable tablets, for oral use SINGULAIR® (montelukast sodium) oral granulesInitial U.S. Approval: 1998
Medication labelWhy this: Advisory · dailymed-prescription
SINGULAIR® is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. SINGULAIR is indicated for prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older. SINGULAIR is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. Because the benefits of SINGULAIR may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see Warnings and Precautions (5.1)], reserve use for patients who have an inadequate response or intolerance to alternative therapies. SINGULAIR is not indicated for the treatment of an acute asthma attack.
- generic_name
- montelukast sodium
- product_names
- montelukast sodium
- ndc
- 78206-171, 78206-171-01, 78206-170, 78206-170-01, 78206-173, 78206-173-01, 78206-172, 78206-172-01, 78206-172-02
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en